FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912791860> ?p ?o ?g. }

• W2912791860 abstract "Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study, we evaluated the effects of aflibercept in first‑line therapy with FOLFOX followed by maintenance with fluoropyrimidine. VELVET was a prospective, single‑arm multicenter phase II study (completed). Patients with previously untreated, unresectable, evaluable or measurable mCRC, with an age ≥18 years, and an ECOG performance status of 0‑2 received 6 cycles of modified FOLFOX7 (5‑FU/folinic acid and oxaliplatin) with aflibercept at 4 mg/kg every 2 weeks followed by maintenance therapy with fluoropyrimidine with aflibercept until disease progression or limiting toxicity. The reintroduction of oxaliplatin was performed at first progression. The primary endpoint was progression‑free survival (PFS) at 6 months. From May, 2013 to May, 2014, 49 patients were included and 48 were evaluable for response. In total, 33 patients (67.4%) were alive without progression at 6 months. The Kaplan‑Meier survival 6‑month and 1‑year PFS rates were 79.1 and 36.1%, respectively, and the median PFS was 9.3 months (95% CI, 8.3‑12.5). The objective response rate was 59.2% (N=29/49). The most common (≥10%) grade 3‑4 adverse events were hypertension (23%), fatigue (15%), neutropenia (12%), neuropathy (12%) and stomatitis (10%). Three (6%) treatment‑related deaths occurred: One from stroke, one from pulmonary embolism and one from neutropenic sepsis. On the whole, this study demonstrates the efficacy of aflibercept in combination with an oxaliplatin‑based regimen in the first‑line therapy of patients with mCRC. A strict monitoring of blood pressure and immediate management of hypertension during therapy is mandatory." @default.
• W2912791860 created "2019-02-21" @default.
• W2912791860 creator A5002063921 @default.
• W2912791860 creator A5004345561 @default.
• W2912791860 creator A5008863246 @default.
• W2912791860 creator A5013525685 @default.
• W2912791860 creator A5020893157 @default.
• W2912791860 creator A5026643846 @default.
• W2912791860 creator A5034922000 @default.
• W2912791860 creator A5035411007 @default.
• W2912791860 creator A5038761404 @default.
• W2912791860 creator A5041015838 @default.
• W2912791860 creator A5042489163 @default.
• W2912791860 creator A5052788938 @default.
• W2912791860 creator A5054670872 @default.
• W2912791860 creator A5061710022 @default.
• W2912791860 creator A5064556770 @default.
• W2912791860 creator A5067302499 @default.
• W2912791860 creator A5072953590 @default.
• W2912791860 creator A5079480540 @default.
• W2912791860 creator A5080127868 @default.
• W2912791860 creator A5083396561 @default.
• W2912791860 date "2019-02-01" @default.
• W2912791860 modified "2023-10-18" @default.
• W2912791860 title "Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase�II study" @default.
• W2912791860 doi "https://doi.org/10.3892/ijo.2019.4709" @default.
• W2912791860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30720091" @default.
• W2912791860 hasPublicationYear "2019" @default.
• W2912791860 type Work @default.
• W2912791860 sameAs 2912791860 @default.
• W2912791860 citedByCount "8" @default.
• W2912791860 countsByYear W29127918602020 @default.
• W2912791860 countsByYear W29127918602021 @default.
• W2912791860 countsByYear W29127918602022 @default.
• W2912791860 countsByYear W29127918602023 @default.
• W2912791860 crossrefType "journal-article" @default.
• W2912791860 hasAuthorship W2912791860A5002063921 @default.
• W2912791860 hasAuthorship W2912791860A5004345561 @default.
• W2912791860 hasAuthorship W2912791860A5008863246 @default.
• W2912791860 hasAuthorship W2912791860A5013525685 @default.
• W2912791860 hasAuthorship W2912791860A5020893157 @default.
• W2912791860 hasAuthorship W2912791860A5026643846 @default.
• W2912791860 hasAuthorship W2912791860A5034922000 @default.
• W2912791860 hasAuthorship W2912791860A5035411007 @default.
• W2912791860 hasAuthorship W2912791860A5038761404 @default.
• W2912791860 hasAuthorship W2912791860A5041015838 @default.
• W2912791860 hasAuthorship W2912791860A5042489163 @default.
• W2912791860 hasAuthorship W2912791860A5052788938 @default.
• W2912791860 hasAuthorship W2912791860A5054670872 @default.
• W2912791860 hasAuthorship W2912791860A5061710022 @default.
• W2912791860 hasAuthorship W2912791860A5064556770 @default.
• W2912791860 hasAuthorship W2912791860A5067302499 @default.
• W2912791860 hasAuthorship W2912791860A5072953590 @default.
• W2912791860 hasAuthorship W2912791860A5079480540 @default.
• W2912791860 hasAuthorship W2912791860A5080127868 @default.
• W2912791860 hasAuthorship W2912791860A5083396561 @default.
• W2912791860 hasBestOaLocation W29127918601 @default.
• W2912791860 hasConcept C121608353 @default.
• W2912791860 hasConcept C126322002 @default.
• W2912791860 hasConcept C141071460 @default.
• W2912791860 hasConcept C143998085 @default.
• W2912791860 hasConcept C2776694085 @default.
• W2912791860 hasConcept C2776705615 @default.
• W2912791860 hasConcept C2776999253 @default.
• W2912791860 hasConcept C2777063308 @default.
• W2912791860 hasConcept C2777802072 @default.
• W2912791860 hasConcept C2778260052 @default.
• W2912791860 hasConcept C2778749236 @default.
• W2912791860 hasConcept C2779804826 @default.
• W2912791860 hasConcept C2780259306 @default.
• W2912791860 hasConcept C2780739268 @default.
• W2912791860 hasConcept C2780962732 @default.
• W2912791860 hasConcept C31760486 @default.
• W2912791860 hasConcept C526805850 @default.
• W2912791860 hasConcept C71924100 @default.
• W2912791860 hasConcept C90924648 @default.
• W2912791860 hasConceptScore W2912791860C121608353 @default.
• W2912791860 hasConceptScore W2912791860C126322002 @default.
• W2912791860 hasConceptScore W2912791860C141071460 @default.
• W2912791860 hasConceptScore W2912791860C143998085 @default.
• W2912791860 hasConceptScore W2912791860C2776694085 @default.
• W2912791860 hasConceptScore W2912791860C2776705615 @default.
• W2912791860 hasConceptScore W2912791860C2776999253 @default.
• W2912791860 hasConceptScore W2912791860C2777063308 @default.
• W2912791860 hasConceptScore W2912791860C2777802072 @default.
• W2912791860 hasConceptScore W2912791860C2778260052 @default.
• W2912791860 hasConceptScore W2912791860C2778749236 @default.
• W2912791860 hasConceptScore W2912791860C2779804826 @default.
• W2912791860 hasConceptScore W2912791860C2780259306 @default.
• W2912791860 hasConceptScore W2912791860C2780739268 @default.
• W2912791860 hasConceptScore W2912791860C2780962732 @default.
• W2912791860 hasConceptScore W2912791860C31760486 @default.
• W2912791860 hasConceptScore W2912791860C526805850 @default.
• W2912791860 hasConceptScore W2912791860C71924100 @default.
• W2912791860 hasConceptScore W2912791860C90924648 @default.
• W2912791860 hasLocation W29127918601 @default.
• W2912791860 hasLocation W29127918602 @default.
• W2912791860 hasOpenAccess W2912791860 @default.
• W2912791860 hasPrimaryLocation W29127918601 @default.
• W2912791860 hasRelatedWork W1970391226 @default.

• next